ESTEVE Announces Strategic Acquisition to Broaden Oncology Portfolio with Medullary Thyroid Cancer Treatment
Barcelona, Spain – June 30, 2025 – ESTEVE, a global pharmaceutical company dedicated to improving people’s lives through innovative medicines, today announced a significant development in its ongoing commitment to advancing cancer care. The company has entered into an agreement to acquire a promising new medicine specifically developed to treat medullary thyroid cancer (MTC). This strategic move is poised to strengthen ESTEVE’s oncology portfolio and address a critical unmet medical need for patients battling this rare and often aggressive form of thyroid cancer.
Medullary thyroid cancer accounts for approximately 3-4% of all thyroid cancers and is characterized by the growth of cancerous cells in the parafollicular cells (C cells) of the thyroid gland. These C cells produce calcitonin, a hormone that plays a role in calcium regulation. While surgical intervention is often the primary treatment, many patients experience disease recurrence or develop advanced, metastatic MTC, for which treatment options can be limited.
The newly acquired medicine, details of which are expected to be further disclosed following the completion of the acquisition, has demonstrated compelling clinical potential in addressing the specific molecular drivers of medullary thyroid cancer. ESTEVE’s investment in this therapy underscores its dedication to developing targeted treatments for complex diseases.
“This acquisition represents a pivotal moment for ESTEVE’s oncology franchise and our mission to bring meaningful therapeutic advancements to patients facing challenging diagnoses,” stated a spokesperson for ESTEVE. “Medullary thyroid cancer is a serious condition where innovative treatment options are desperately needed. We are confident that this medicine, once integrated into our portfolio, will offer a new avenue of hope for patients and their healthcare providers.”
The transaction is subject to customary closing conditions and regulatory approvals. ESTEVE anticipates that the integration of this medicine will be a thorough and well-managed process, ensuring a seamless transition for ongoing clinical trials and future commercialization efforts.
With this acquisition, ESTEVE is reinforcing its position as a key player in the pharmaceutical industry, particularly within the oncology space. The company’s strategic focus on rare and complex diseases, coupled with its robust research and development capabilities, positions it well to deliver on the promise of this new therapy and contribute significantly to the fight against medullary thyroid cancer. Further information regarding the specific medicine and its development pathway will be shared by ESTEVE as the acquisition progresses.
ESTEVE to acquire medicine to treat medullary thyroid cancer
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘ESTEVE to acquire medicine to treat medullary thyroid cancer’ at 2025-06-30 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.